Skip to main content

Specialty Pharmacy

  • PhRMA elects new board members, adds member company
    WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday officially elected new board members and welcomed its latest member company, UBC. 
     

  • Bristol-Myers Squibb remains committed to Opdivo-Yervoy combo lung cancer treatment

    PRINCETON, N.J. — Despite word a week ago that Bristol-Myers Squibb will not seek accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer, the company asserted it is committed to the development of the drug combination.

  • Walgreens opens first Community specialty banner in Iowa

    DEERFIELD, Ill.  — Walgreens will be opening its first specialty pharmacy in Iowa next month, according to a report in The Des Moines Register.

    The 2,000 square foot pharmacy will open under the Community, A Walgreens Pharmacy banner and will cater to patients with complex medical conditions such as cancer, HIV/AIDS and transplants.

  • Johnson & Johnson to buy Actelion for $30B

    NEW BRUNSWICK, N.J. — Johnson & Johnson will buy Switzerland-based Actelion for $30 billion, or $280 per Actelion share. As part of the transaction, Actelion will spin off its drug discovery operations and early-stage clinical development assets into a newly created company to its shareholders in the form of a dividend immediately prior to the deal closing.

  • PhRMA launches Go Boldly campaign

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Monday launched its new multi-year advertising and public affairs initiative, Go Boldly. The campaign is aimed at highlighting those in the industry driving innovation and pointing to the opportunity that exists in tackling complex health conditions. 

  • Bristol-Myers Squibb decides against accelerated approval for Opdivo/Yervoy combo for lung cancer
    PRINCETON, N.J. — Bristol-Myers Squibb has announced that it will not seek an accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer. 
     
    The company said the announcement was “based on a review of data available at this time,” and noted that they would not provide additional details to “protect the integrity of ongoing registrational studies.”
     

  • FDA issues draft guidance on biosimilar interchangeability
    SILVER SPRING, Md. — The Food and Drug Administration recently shared the first draft guidance addressing the interchangeability of biosimilar drugs and their reference products. 
     

  • Mayne Pharma launches Fabior, Sorilux
    GREENVILLE, N.C. — Mayne Pharma on Wednesday announced the launch of Fabior (tazarotene, 0.1%) Foam and Sorilux (calcipotiene, 0.005%) Foam. Mayne Pharma acquired the products from GSK in August 2016, and they complement the company’s Doryx, the first branded product in its specialty brands division that it launched in 2015. 
     
X
This ad will auto-close in 10 seconds